As of June 30, 2026, Silicon Laboratories Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.04545454 Sh carries a market capitalization of 37.32B, placing it among publicly traded companies globally. Its enterprise value stands at 35.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 37.32B |
| Enterprise Value | 35.27B |
Silicon Laboratories Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.04545454 Sh's next confirmed earnings release is scheduled for November 4, 2026.
| Earnings Date | 11/4/2026 |
As of June 30, 2026, Silicon Laboratories Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.04545454 Sh has 729.88M shares outstanding.
| Shares Outstanding | 729.88M |
These figures are as of June 30, 2026. The price-to-sales ratio is 8.34, and the price-to-book ratio stands at 6.59.
| PS Ratio | 8.34 |
| PB Ratio | 6.59 |
| P/TBV Ratio | 10.32 |
| P/FCF Ratio | -1,313.77 |
| P/OCF Ratio | 215.64 |
These figures are as of June 30, 2026. The EV/Sales ratio of 7.97 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 35.27B versus a market cap of 37.32B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 7.97 |
As of June 30, 2026, Silicon Laboratories Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.04545454 Sh maintains a current ratio of 5.41, meaning it holds 5.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.41 |
| Quick Ratio | 3.84 |
| Interest Coverage | -10.81 |
Over the twelve months ended June 30, 2026, Silicon Laboratories Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.04545454 Sh posted a negative return on equity (ROE) of -3.63, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.16, reflecting losses generated across the asset base. The company generates approximately 2.30M in revenue per employee across its workforce of 1,919.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.30 indicates how many times Silicon Laboratories Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.04545454 Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -3.63 |
| Return on Assets (ROA) | -3.16 |
| Revenue Per Employee | 2.30M |
| Employee Count | 1,919.75 |
| Inventory Turnover | 3.30 |
Over the twelve months ended June 30, 2026, Silicon Laboratories Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.04545454 Sh recorded 35.86M in income tax expense. The company reported a pretax loss of -166.30M and -202.15M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 35.86M |
As of the close on August 13, 2026, Silicon Laboratories Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.04545454 Sh's stock has gained approximately 59.82% over the past 52 weeks.
| 52-Week Price Change | 59.82% |
Over the twelve months ended June 30, 2026, Silicon Laboratories Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.04545454 Sh generated 4.42B in revenue and converted that into -202.15M in net income, yielding earnings per share of -0.28. EBITDA reached -51.58M, while operating income came in at -224.03M.
| Revenue | 4.42B |
| Gross Profit | 2.68B |
| Operating Income | -224.03M |
| Pretax Income | -166.30M |
| Net Income | -202.15M |
| EBITDA | -51.58M |
| EBIT | -224.03M |
| Earnings Per Share (EPS) | -0.28 |
These figures are as of June 30, 2026. Total book value stands at 5.66B, with working capital of 2.83B providing operational flexibility.
| Cash & Cash Equivalents | 2.05B |
| Net Debt | -1.87B |
| Equity (Book Value) | 5.66B |
| Book Value Per Share | 7.75 |
| Working Capital | 2.83B |
Silicon Laboratories Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.04545454 Sh produced 171.06M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -199.14M in capital expenditures, free cash flow totaled -28.08M - equivalent to -0.04 per share.
| Operating Cash Flow | 171.06M |
| Capital Expenditures | -199.14M |
| Free Cash Flow | -28.08M |
| FCF Per Share | -0.04 |
Over the twelve months ended June 30, 2026, Silicon Laboratories Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.04545454 Sh posted a gross margin of 60.61, reflecting its pricing power and cost economics. The operating margin of -5.06 and net profit margin of -4.57 provide insight into operational efficiency.
| Gross Margin | 60.61 |
| Operating Margin | -5.06 |
| Pretax Margin | -3.76 |
| Profit Margin | -4.57 |
| EBITDA Margin | -1.17 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.08: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.20, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Silicon Laboratories Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.04545454 Sh shareholders.
| Shareholder Yield | 0.20 |
| FCF Yield | -0.08 |
As of June 30, 2026, Silicon Laboratories Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.04545454 Sh has an Altman Z-Score of 30.45, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 30.45 |